Paul T.  Lehr net worth and biography

Paul Lehr Biography and Net Worth

General Counsel of Longeveron
Paul Lehr (General Counsel and Secretary) joined Longeveron in 2016 and serves as General Counsel and Corporate Secretary.  Over the past 20 years, Mr. Lehr has held senior legal and executive positions in corporate, non-profit, and research settings.  Mr. Lehr started his legal career as a law clerk for a United States Federal Judge and thereafter practiced law at a leading Miami law firm for 5 years, with experience in healthcare and business. Thereafter, Mr. Lehr focused his efforts in the cardiac rehabilitation field as President and General Counsel of a non-profit research foundation and for-profit cardiac rehabilitation program.  With the research serving as the foundation of the for-profit arm of the cardiac rehabilitation program, Mr. Lehr negotiated a master franchise agreement with a leading Indian healthcare operator with 100+ facilities across India and the Middle East, then co-lead negotiations with the Centers for Medicare & Medicaid Services to successfully secure CMS reimbursement of their intensive cardiac rehabilitation program.  Mr. Lehr has also served since 2011 as CEO and co-founder of HeartGenomics, a biotech firm based on intellectual property Mr. Lehr licensed from the UM Miller School of Medicine.  Mr. Lehr earned his B.A. from Brown University, and his J.D. with honors from University of Florida College of Law.

How old is Paul T. Lehr?

Mr. Lehr is currently 56 years old. There are 6 older executives and no younger executives at Longeveron. The oldest executive at Longeveron is Mr. Mohamed Wa'el Ahmed Hashad, CEO & Director, who is 62 years old. Learn More on Paul T. Lehr's age.

How do I contact Paul T. Lehr?

The corporate mailing address for Mr. Lehr and other Longeveron executives is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. Longeveron can also be reached via phone at 305-302-7158 and via email at [email protected]. Learn More on Paul T. Lehr's contact information.

Has Paul T. Lehr been buying or selling shares of Longeveron?

Paul T. Lehr has not been actively trading shares of Longeveron during the last quarter. Most recently, on Thursday, October 7th, Paul T. Lehr bought 175 shares of Longeveron stock. The stock was acquired at an average cost of $33.40 per share, with a total value of $5,845.00. Learn More on Paul T. Lehr's trading history.

Who are Longeveron's active insiders?

Longeveron's insider roster includes James Clavijo (CFO), Geoff Green (CEO), Joshua Hare (Insider), Paul Lehr (General Counsel), and Rock Soffer (Director). Learn More on Longeveron's active insiders.

Are insiders buying or selling shares of Longeveron?

During the last year, Longeveron insiders bought shares 2 times. They purchased a total of 1,500 shares worth more than $20,050.00. During the last year, insiders at the sold shares 2 times. They sold a total of 1,353 shares worth more than $47,234.40. The most recent insider tranaction occured on January, 10th when Director Cathy Ross bought 500 shares worth more than $6,550.00. Insiders at Longeveron own 24.3% of the company. Learn More about insider trades at Longeveron.

Information on this page was last updated on 1/10/2024.

Paul T. Lehr Insider Trading History at Longeveron

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2021Buy175$33.40$5,845.00View SEC Filing Icon  
See Full Table

Paul T. Lehr Buying and Selling Activity at Longeveron

This chart shows Paul T Lehr's buying and selling at Longeveron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Longeveron Company Overview

Longeveron logo
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $3.25
Low: $3.20
High: $3.64

50 Day Range

MA: $5.53
Low: $3.13
High: $10.20

2 Week Range

Now: $3.25
Low: $2.92
High: $44.00

Volume

148,440 shs

Average Volume

32,302 shs

Market Capitalization

$8.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32